Novel protein–protein interactions of TPPII, p53, and SIRT7

Molecular and Cellular Biochemistry

Volumn 409, Issue 1-2, 2015, Pages 13-22

  Nahálková, Jarmila ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Aging; Apoptosis; Cellular senescence; p53; SIRT7; TPPII

Indexed keywords

CORE PROTEIN; EPITOPE; PROTEIN ANTIBODY; PROTEIN P53; PROTEIN TPPII; SIRTUIN 7; UNCLASSIFIED DRUG; AMINOPEPTIDASE; DIPEPTIDYL PEPTIDASE; ISOPROTEIN; SERINE PROTEINASE; SIRT7 PROTEIN, HUMAN; SIRTUIN; TRIPEPTIDYL-PEPTIDASE 2;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL FRACTIONATION; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LIVER; LONGEVITY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SENESCENCE; AMINO ACID SEQUENCE; ANIMAL; CELL AGING; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; SEQUENCE ALIGNMENT; TUMOR CELL LINE;

AMINO ACID SEQUENCE; AMINOPEPTIDASES; ANIMALS; APOPTOSIS; CELL AGING; CELL LINE, TUMOR; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; HEK293 CELLS; HELA CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PROTEIN INTERACTION MAPS; PROTEIN ISOFORMS; SEQUENCE ALIGNMENT; SERINE ENDOPEPTIDASES; SIRTUINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84942883231     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2507-y     Document Type: Article

References (37)

1. Lévy F, Burri L, Morel S, Peitrequin AL, Lévy N et al (2002) The final N-terminal trimming of a subaminoterminal proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two peptidases. J Immunol 169:4161–4171
2. Bålöw R-M, Ragnarsson U, Zetterqvist O (1983) Tripeptidyl aminopeptidase in the extralysosomal fraction of rat liver. J Biol Chem 258:11622–11628
3. Reits E, Neijssen J, Herberts C, Benckhuijsen W, Janssen L (2004) A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20:495–506
4. York IA, Bhutani N, Zendzian S, Goldberg AL, Rock KL (2006) Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J Immunol 177:1434–1443
5. Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG (2001) C-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol 3:283–288
6. Duensing S, Darr S, Cuevas R, Melquiot N, Brickner AG et al (2010) Tripeptidyl peptidase II is required for c-MYC-induced centriole over duplication and a novel therapeutic target in c-MYC-associated neoplasms. Gen Cancer 1:883–892
7. Stavroupoulou V, Xie J, Henriksson M, Tomkinson B, Imreh S et al (2005) Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II. Cancer Res 65:1361–1368
8. Huai J, Firat E, Nil A, Million D, Gaedicke S et al (2008) Activation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout mice. Proc Natl Acad Sci USA 105:5177–5182
9. Huber K, Superti-Furga G (2011) After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg Med Chem 19:3616–3624
10. Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T et al (2008) Sirt7 increases stress resistance of cardiomyocytes and prevents inflammatory cardiomyopathy in mice. Circ Res 102:703–710
11. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16:4623–4635
12. Martínez-Redondo P, Santos-Barriopedro I, Vaquero A (2012) A big step for SIRT7, one giant leap for sirtuins in cancer. Cancer Cell 21:719–721
13. Nahálková J, Tomkinson B (2014) TPPII, MYBBP1A and CDK2 form a protein-protein interaction network. Arch Biochem Biophys 564:128–135
14. Levine AJ, Hu W, Feng Z (2006) The P53 pathway: what questions remain to be explored? Cell Death Differ 13:1027–1036
15. Driver JA (2012) Understanding the link between cancer and neurodegeneration. J Geriatr Oncol 3:58–67
16. Tomkinson B, Hansen M, Cheung WF (1997) Structure-function studies of recombinant murine tripeptidyl-peptidase II: the extra domain which is subject to alternative splicing is involved in complex formation. FEBS Lett 405:277–280
17. Tomkinson B, Ni Laoi B, Wellington K (2002) The insert within the catalytic domain of tripeptidyl-peptidase II is important for the formation of the active complex. Eur J Biochem 269:1438–1443
18. Garner RC, Miller EC, Miller JA (1972) Liver microsomal metabolism of aflatoxin B1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res 32:2058–2066
19. Söding J (2005) Protein homology detection by HMM–HMM comparison. Bioinformatics 21:951–960
20. Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ (2009) Jalview version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 25:1189–1191
21. Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius K-J et al (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 3:995–1000
22. Tsai YC, Greco TM, Boonmee A, Miteva Y, Cristea IM (2012) Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics 11:60–76
23. Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M et al (2012) SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 487:114–118
24. Martínez-Redondo P, Santos-Barriopedro I, Vaquero A (2012) A big step for SIRT7, one giant leap for sirtuins in cancer. Cancer Cell 21:719–721
25. Rose C, Vargas F, Facchinetti P, Bourgeat P, Bambal RB et al (1996) Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature 380:403–409
26. Firat E, Huai J, Saveanu L, Gaedicke S, Aichele P et al (2007) Analysis of direct and cross-presentation of antigens in TPPII knockout mice. J Immunol 179:8137–8145
27. Lilling G, Novitsky E, Sidi Y, Bakhanashvili M (2003) p53-associated 35′ exonuclease activity in nuclear and cytoplasmic compartments of cells. Oncogene 22:233–245
28. Akaogi K, Ono W, Hayashi Y, Kishimoto H, Yanagisawa J (2013) MYBBP1A suppresses breast cancer tumorigenesis by enhancing the p53 dependent anoikis. BMC Cancer 13:65–78
29. Karni-Schmidt O, Zupnick A, Castillo M, Ahmed A, Matos T et al (2008) p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. J Cell Sci 121:4098–4105
30. Preta G, Klark R, Glas R (2009) A role for nuclear translocation of tripeptidyl-peptidase II in reactive oxygen species-dependent DNA damage responses. Biochem Biophys Res Comm 389:575–579
31. Vakhrusheva O, Braeuer D, Liu Z, Braun T, Bober E (2008) Sirt7-dependent inhibition of cell growth and proliferation might be instrumental to mediate tissue integrity during aging. J Physiol Pharmacol 59:201–212
32. Owen HR, Elser M, Cheung E, Gersbach M, Kraus L et al (2007) MYBBP1a is a novel repressor of NF-κB. J Mol Biol 366:725–736
33. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr (1998) NF-ΚB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680–1683
34. Shay JW, Pereira-Smith OM, Wright WE (1991) A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 196:33–39
35. Itahana K, Dimri G, Campisi J (2001) Regulation of cellular senescence by p53. Eur J Biochem 268:2784–2791
36. Donehower LA (2002) Does p53 affect organismal aging? J Cell Physiol 192:23–33
37. Nilsson A, Fälth M, Zhang X, Kultima K, Sköld K et al (2009) Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease. Mol Cell Proteomics 8:1094–1104